Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world (14).
Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is used in some cases as a bridge to liver transplantation. It is also used for patients with unresectable HCC, and has been shown to improve survival (13). Early assessment of the effectiveness of TACE is critical in planning future therapy (5). Assessment of tumor response after chemoembolization on CT is generally based on the radio-opacity of the iodized oil that selectively accumulates in the tumor in addition to tumor enhancement and tumor size on contrast enhanced CT. Iodized oil impairs the assessment of residual tumor enhancement on contrast enhanced CT (25).
In contrast to CT, the high concentration of iodized oil after chemoembolization does not affect MR signal intensity. Enhancing portions of the tumor are presumed to be viable, whereas nonenhancing portions are presumed to be necrotic.
The disadvantage of contrast-enhanced MRI is the incapability to distinguish viable cells from reactive granulation tissue. (25).
Diffusion-weighted imaging (DWI), a functional MRI technique, detects MR signal changes in tissues due to water proton motion that varies based upon the degree of cell membrane integrity. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion. This mobility of water is quantified by a constant known as the apparent diffusion coefficient (ADC) (4). Diffusionweighted MRI (DWI) provides unique information related to tumor cellularity and the integrity of cell membranes and thus may be sensitive to changes in the tumor microenvironment that occur after treatment (12).
Patients & Methods:
Thirty patients were included in this prospective study. The study was performed between November 2011 & September 2013. Patients included in the study were all males, ranging in age between 51 & 73 years with a mean age of 58.2 years. They were Ain Shams University hospital patients. All patients were diagnosed as HCC patients based on typical enhancement pattern on triphasic CT scan. Patients with high serum creatinine (above 1.4 mg %), are excluded from this study, for fear of contrast induced nephrogenic systemic fibrosis. All thirty patients are prospectively studied. All thirty patients have undergone chemoembolization for 30 focal lesions. In patients with multiple HCC focal lesions the largest one was treated.
All patients were subjected to Complete liver profile, Abdominal MRI within 10 days before chemoembolization including pre-and post contrast dynamic MRI & diffusion-weighted imaging for 18 patients & diffusion-weighted imaging only for 12 patients in addition to Abdominal MRI one month after chemoembolization including pre-and post contrast dynamic MRI & diffusion-weighted imaging for all patients. MRI imaging: A 1.5-T MR unit (Achieva; Philips Medical Systems, Best, the Netherlands) was used, using a phased array coil to cover the whole liver. a) Pre-contrast imaging, with respiratory triggering included: T1 weighted (T1W) in & out of phase gradient echo sequence (GRE): repetition time (TR) = 10 ms, echo time (TE) = 4.6 ms, NEX (number of excitations) 2, flip angle 15, matrix 150x236 with a field of view as small as possible, slice thickness 4 mm and slice gap 0.5 mm, T1 weighted (T1W) gradient echo sequence (GRE) with fat suppression (FS): repetition time (TR) = 100-200ms, echo time (TE) = 10 ms, NEX 1, flip angle 15, matrix 150x236 with a field of view as small as possible, slice thickness 4 mm and slice gap 0.5 mm & T2 weighted (T2W) images (fast spin echo sequence) (FS): TR = 2000ms, TE= 90-120 ms, NEX 3, matrix 150x236 with a field of view as small as possible, slice thickness 4 mm and slice gap 0.5 mm. b) Dynamic study: Dynamic study was performed after bolus injection of 0.1mmol/kg body weight of Gd-DTPA at a rate of 2ml/s, flushed with 20ml of sterile 0.9 % saline solution from the antecubital vein. The injection of contrast media and saline solution was performed using pump injector. Breathhold dynamic imaging using T1 weighted gradient echo sequence, with fat suppression (thrive) was performed in a triphasic manner [arterial phase (16-20 sec.) , portovenous phase (45-60 sec.) and delayed equilibrium phase (3-5 min.)] after administration of contrast media. Subtraction images were also performed for each phase. The mean diameter of the enhancing tumor tissue before treatment was 5.9 mm + 1.7 standard deviation (SD) & after treatment was 1.5 mm + 1.3 SD with statistically significant difference (P value less than 0.001). The mean tumor ADC value before treatment was 1.2 x 10 −3 mm 2 /sec + 0.1 SD. This value increased to 1.49 x 10 −3 mm 2 /sec + 0.3 SD after treatment, with statistically significant difference (P value less than 0.001). The mean serum alpha fetoprotein level before treatment was 2031 ng/ml + 5944 SD that decreased to 843 ng/ml + 1845 SD after treatment, with statistically non-significant difference (P value more than 0.05). According to Mann Whitney-test (17) there was a statistically significant difference between both groups as regard: The diameter of the enhancing tumor tissue after chemoembolization (P-value less than 0.05), the percent change in the diameter of the enhancing tumor tissue after treatment (P-value less than 0.001), the mean ADC of the focal lesion after treatment (P-value less than 0.05), the percent change in the mean ADC after treatment (P-value less than 0.001) & the serum alpha fetoprotein before & after treatment (Pvalue less than 0.05) ( Transcatheter arterial hepatic angiography shows the focal lesion to take supply from two arteries, the medial one being the principal feeder, with minor contribution from the lateral one ( fig.6 ). Chemo-lipoidol injection is done ( fig.7) , with successful embolization of the medial vessel. 
Case 2:
A 73 year old male patient presented with a focal lesion in the right lobe of the liver, at segment VIII, measuring 4. 
Discussion
Assessment of tumor viability after TACE is important for evaluation of tumor response, subsequent treatment planning, and evaluation for liver transplantation. Although histopathologic assessment of the treated tumor remains the most definitive method to determine viability, it is not feasible as a method for follow-up (23).
The goal of local treatment of HCC is tumor necrosis rather than tumor shrinkage. In time, it has become evident that RECIST standards for assessment of tumor response to therapy are not enough for response evaluation in HCC after chemoembolization, because they depend on changes in tumor size & do not take into account changes in tumor viability that may be associated with tumor response (6). In 2000, the European Association for the Study of the Liver (2) proposed that the optimal method to evaluate response to local treatment is to assess the reduction in viable tumor volume, which is seen as a reduction in enhancing areas on contrast-enhanced images. The currently used method for assessment of HCC response to chemoembolization is the modified RECIST criteria that depend on the arterial enhancement of the viable tumor tissue (15). Although contrast-enhanced CT is able to reveal residual or recurrent tumors as areas of arterial enhancement, it is often difficult to assess accurately contrast enhancement in such areas adjacent to retained iodized oil on CT, because of the beam-hardening artifacts caused by such iodized oil. Residual viable tumor tissue is better depicted by gadolinium-enhanced MR imaging that is barely influenced by the presence of iodized oil (7). Kalb et al., (9) investigated the usefulness of early (1-month) post-therapy contrast-enhanced MR imaging for the detection of residual disease after chemoembolization for HCC. The results showed good sensitivity for the ability of the 1-month follow-up MR imaging study to predict the presence of residual disease using persistent arterial phase contrast enhancement as a marker of the viable tumor with 100% specificity in predicting complete response to therapy. Murakami et al. (18) reported a sensitivity of 80% with the use of dynamic MR imaging with gadopentetate contrast medium in 10 patients after chemoembolization with Lipoidol. Viable tumor was shown to correlate with early hyperintense enhancement, whereas lack of early enhancement corresponded to necrotic regions of the tumor. Ito et al. (8) reported a sensitivity of 92% with the use of multisection dynamic MR with gadopentetate contrast medium to assess tumor viability in 13 patients after chemoembolization with Lipoidol. Riaz et al. (19) showed that the application of strict radiologic response criteria (EASL and WHO) after chemoembolization had a reasonable ability to predict actual tumor necrosis. These data consolidated the belief that changes in the amount of enhancing tissue after chemoembolization correspond to the actual necrosis. Kim et al. (13) observed that qualitative assessment of tumor necrosis of HCC following TACE based on subtracted datasets of contrast-enhanced MRI had an excellent correlation with histopathology, with higher interobserver agreement when compared with non-subtracted dataset, and a statistically significant difference for predicting complete tumor necrosis at the arterial phase.
Image subtraction was used in assessment of the post contrast dynamic series in the current study. This was of great value in demonstrating enhancement in the T1 hyperintense lesions. The use of subtracted image data sets was also reported in previous similar studies ( 13 & 16) . In this cohort, we found a statistically significant difference in the diameter of the enhancing tumor tissue before and after chemoembolization, as well as, the percent change in the diameter of the enhancing tumor tissue after treatment between patients with complete response & those with partial response.
Response assessment is a newly developing scope of DWI that does not require the use of contrast media. The first studies of this issue were done in rabbit VX2 tumor models intra-procedural DWI in predicting a future anatomical response 1 mo after TACE. Specifically, they showed that patients whose ADC value increased or decreased from baseline by > 15% immediately after TACE had a 100% rate in predicting a positive EASL response after one month.
In the current study, the mean tumor ADC value increased from 1.2+0.1 x 10 −3 mm 2 /sec to 1.49+0. Also of note is the difference in the percent increase in the ADC value after chemoembolization. In their study (11 & 20) , the increase in the mean ADC value of the focal lesions was 20% and 15.4% respectively, whereas, in the present study, it was 11.6+7% in patients with partial response, and 34.6+10% in patients with complete response with a statistically significant difference between the two groups.
According to the current study, the best predictive cut off value for differentiation between complete & partial response was 24 % increase in the mean ADC value, with 99 % sensitivity, 84 % specificity, 90 % positive predictive value, 99 % negative predictive value & 86 % accuracy. The % increase of the mean ADC value is considered better positive than negative predictor for response to treatment. Mannelli et al. (16) reported 75% sensitivity & 87.5 % specificity of a pre-treatment tumor mean ADC cutoff value greater than 2.16 x 10 −3 mm 2 /sec for prediction of complete tumor necrosis. In addition, the present study showed a significant positive correlation between the percent change in the mean ADC value & the percent change in the diameter of the enhancing tumor tissue after chemoembolization. These results consolidate the belief that DWI is potentially useful for followup after TACE by showing changes in ADC value as an alternative to contrast-enhanced MRI in the care of patients who cannot receive gadolinium contrast material, such as patients with renal insufficiency at risk of nephrogenic systemic fibrosis. On the other hand there was no statistically significant correlation between the percent change in the serum AFP level & the percent change in the diameter of the enhancing tumor tissue after treatment. This means that serum AFP level cannot be used solely in the follow up of patients after chemoembolization. Yuan et al. (24) proposed that high pretreatment mean ADC values of HCC were predictive of poor response to chemoembolization. In the current study, there was no statistically significant difference between patients with complete & partial response as regard the pre-treatment mean ADC value and this was in agreement with Sahin et al. (20) . However, further studies on this issue with larger numbers of patients are needed to reach a firmer conclusion.
In addition to the quantitative assessment of the DWI and ADC value measurements, we also assessed the DW images qualitatively (using the high b value images) for relative diffusion restriction in portions of the tumor that show arterial enhancement in the dynamic images. This was also done in conjunction with reviewing the angiographic images before & after chemoembolization. Also, the change in the shape & distribution of the histogram curve after chemoembolization was investigated & correlated with the tumor response to treatment.
Homogenous, thin rim enhancement around the tumor on delayed gadolinium-enhanced images represents chemoembolization-induced vasculitis, inflammation, and granulation tissue after local treatment (21). Contrast enhancement in granulation tissue is believed to be caused by increased capillary permeability and increased distribution of gadolinium (25). On the contrary, the presence of nodular ring enhancement should cast doubt on local progression. Yet, it is still difficult to detect small residual areas located in the capsule. In those situations, DWI may have a promising role in the differentiation of necrosis and viable tumor, as ADC values increase in the presence of necrosis (23). Acknowledgment: Special thanks to Dr: Mohammed El-gharib, the interventional radiologist who performed chemoembolization for the patients of the study. 
